Rinvoq (Upadacitinib) – Atopic Dermatitis | DengYueMed

Rinvoq Application Scope

Rinvoq is an oral, once-daily Janus kinase (JAK) inhibitor (upadacitinib) used to treat various inflammatory and autoimmune diseases.

Characteristics

• Ingredients: Upadacitinib

• Properties:

  • JAK1-selective inhibitor that reduces inflammatory signaling.

  • Approved for rheumatoid arthritis, psoriatic arthritis

  • Ankylosing spondylitis and giant cell arteritis

  • Non-radiographic axial spondyloarthritis, ulcerative colitis,

  • Crohn’s disease and moderate-to-severe atopic dermatitis

• Packaging Specification: Bottles containing 30 extended-release tablets

• Storage: Store at 2–25 °C (36–77 °F) in the original bottle to protect from moisture.

• Expiry Date: See container label; typical shelf-life ~24 months from manufacture.

• Executive Standard:

  • Follows FDA’s Prescribing Information

  • EMA’s Summary of Product Characteristics

• Approval Number: US FDA: NDA 211675; EU approval under EMA

• Date of Revision: FDA label updated May 2025; major revisions June 2021.

• Manufacturer: AbbVie Inc., with distribution per regional approvals.

Guidelines for the Use of Rinvoq

• Dosage and Administration:

  • Adults (RA, PsA, AS, nr-axSpA, GCA): 15 mg once daily; 30 mg if needed.

  • Atopic Dermatitis (≥12 yrs):

    • Start 15 mg daily; increase to 30 mg if inadequate response

    • 15 mg for ≥65 yrs or renal/hepatic impairment

  • Ulcerative Colitis & Crohn’s Disease:

    • Induction: 45 mg daily (8–12 weeks)

    • Maintenance: 15 mg (or 30 mg per condition)

  • Administration:

    • Take the tablet whole with or without food

    • Do not crush or chew

 

• Adverse Reactions:

  • ≥1%:

    • upper respiratory infections, herpes simplex/zoster, bronchitis

    • nausea, cough, fever, acne, headache;

  • rare hypersensitivity; serious infections, malignancies, and thrombosis documented.

• Contraindications: Known hypersensitivity to upadacitinib or excipients.

• Precautions: 

  • screen for active infections (TB, hepatitis);
  • monitor lymphocytes, neutrophils, hemoglobin, liver enzymes, lipids;
  • caution with GI perforation risk;
  • embryo–fetal toxicity – advise contraception; avoid live vaccines.

Rinvoq Interactions

• Drug Interactions:

  • Avoid strong CYP3A4 inducers (e.g., rifampin);

  • Reduce dose with strong inhibitors (e.g., ketoconazole) to 15 mg daily.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.